Impact of adverse events on costs and quality of life in protease inhibitor-based combination therapy for hepatitis C

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 12, Issue 3, 2012, Pages 335-343

  Gao, Xin ^a   Stephens, Jennifer M ^a   Carter, John A ^b   Haider, Seema ^b   Rustgi, Vinod K ^c  

^a PHARMERIT INTERNATIONAL   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^c GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

adverse events; hepatitis C; protease inhibitors; quality of life; treatment burden

Indexed keywords

BOCEPREVIR; CITALOPRAM; HYDROCORTISONE; LOPERAMIDE; PEGINTERFERON; PLACEBO; PROTEINASE INHIBITOR; RIBAVIRIN; TELAPREVIR;

ANEMIA; COMBINATION CHEMOTHERAPY; COST BENEFIT ANALYSIS; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG WITHDRAWAL; GENOTYPE; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH ECONOMICS; HEPATITIS C; HUMAN; PREVALENCE; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; SHORT FORM 36; TREATMENT DURATION;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEALTH CARE COSTS; HEPATITIS C; HUMANS; INTERFERONS; PROTEASE INHIBITORS; QUALITY OF LIFE; RIBAVIRIN;

EID: 84864206329     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.12.10     Document Type: Review

References (27)

1. Brown RS Jr, Gaglio PJ. Scope of worldwide hepatitis C problem. Liver Transpl. 9(11), S10-S13 (2003
2. Su J, Brook RA, Kleinman NL, Corey-Lisle P. The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefit costs. Hepatology 52(2), 436-442 (2010
3. McHutchison JG, Manns MP, Muir AJ et al.; PROVE3 Study Team. Telaprevir for previously treated chronic HCV infection. N. Engl. J. Med. 362(14), 1292-1303 (2010)
4. Hézode C, Forestier N, Dusheiko G et al.; PROVE2 Study Team. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med. 360(18), 1839-1850 (2009
5. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347(13), 975-982 (2002
6. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 358(9286), 958-965 (2001
7. Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology 35(3), 704-708 (2002
8. Kwo PY, Lawitz EJ, McCone J et al.; SPRINT-1 Investigators. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): An open-label, randomised, multicentre Phase 2 trial. Lancet 376(9742), 705-716 (2010
9. McHutchison JG, Everson GT, Gordon SC et al.; PROVE1 Study Team. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N. Engl. J. Med. 360(18), 1827-1838 (2009
10. Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health related quality of life: A systematic review and quantitative assessment. Hepatology 41(4), 790-800 (2005
11. Bacon BR, Gordon SC, Lawitz E et al.; HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV enotype 1 infection. N. Engl. J. Med. 364(13), 1207-1217 (2011
12. Jacobson IM, McHutchison JG, Dusheiko G et al.; ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 364(25), 2405-2416 (2011
13. Poordad F, McCone J Jr, Bacon BR et al.; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 364(13), 1195-1206 (2011
14. Zeuzem S, Andreone P, Pol S et al.; Realizes tudy team. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 364(25), 2417-2428 (2011
15. Perrillo R, Rothstein KD, Rubin R et al. Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2a vs the combination of interferon alpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis C. J. Viral Hepat. 11(2), 157-165 (2004
16. Cotler SJ, Patil R, McNutt RA et al. Patients' values for health states associated with hepatitis C and physicians' estimates of those values. Am. J. Gastroenterol. 96(9), 2730-2736 (2001
17. Devine EB, Cross JT, Kowdley KV, SulliVan SD. The cost of treating ribavirininduced anemia in hepatitis C: The impact of using recombinant human erythropoietin. Curr. Med. Res. Opin. 23(6), 1463-1472 (2007
18. Zhang H, Mehra M, DiBello J. Increasing chronic hepatitis C treatment rate is a cost-saving strategy. Presented at: The 14th Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research. Orlando, FL, USA, 16-20 May 2009
19. Zhang H, Mehra M, DiBello J. US hepatitis C burden assessment from a transition model. Presented at: The 14th Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research. Orlando, FL, USA, 16-20 May 2009
20. Afdhal NH, Dieterich DT, Pockros PJ et al.; Proactive Study Group. Epoetin alfa maintains ribavirin dose in HCV-infected patients: A prospective, double-blind, randomized controlled study Gastroenterology 126(5), 1302-1311 (2004
21. Chaiwat O, Lang JD, Vavilala MS et al. Early packed red blood cell transfusion and acute respiratory distress syndrome after trauma. Anesthesiology 110(2), 351-360 (2009
22. Martín-Santos R, Díez-Quevedo C, Castellví P et al. De novo depression and anxiety disorders and influence on adherence during peginterferon-alpha-2a and ribavirin treatment in patients with hepatitis C. Aliment. Pharmacol. Ther 27(3), 257-265 (2008
23. Dan AA, Martin LM, Crone C et al. Depression, anemia and health-related quality of life in chronic hepatitis C. J. Hepatol. 44(3), 491-498 (2006
24. Hollander A, Foster GR, Weiland O. Health-related quality of life before, during and after combination therapy with interferon and ribavirin in unselected Swedish patients with chronic hepatitis C. Scand. J. Gastroenterol. 41(5), 577-585 (2006
25. Dan AA, Kallman JB, Wheeler A et al. Health-related quality of life in patients with non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 26(6), 815-820 (2007
26. Hassanein T, Cooksley G, Sulkowski M et al. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J. Hepatol. 40(4), 675-681 (2004
27. Sjogren MH, Sjogren R Jr, Lyons MF et al. Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin. Dig. Dis. Sci. 52(6), 1540-1547 (2007)